This SEC filing is a big deal for a few reasons.
-It’s “proof” that the CEO isnt just saying he’s going SEC current.
-It’s “proof” a private placement at .05 is happening with a private investor.
-If an investor is willing to put $5,000,000 on the line at .05 (discounted restricted shares) how much higher is this worth? 5x that easy imo.
-CEO is following through with what he said in PR and via shareholder inquiry
Current Report Filing (8-k)
Source: Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report ( Date of earliest event reported )
October 3, 2017 ( September 25, 2017 )
ALR TECHNOLOGIES INC.
(Exact name of registrant as specified in its charter)
NEVADA
(State or other jurisdiction of incorporation)
000-30414
(Commission File No.)
7400 Beaufont Springs Drive
Suite 300
Richmond, Virginia 23225
(Address of principal executive offices) (Zip Code)
(804) 554-3500
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01 REGULATION FD DISCLOSURE.
On September 25, 2017, the Company issued a press release announcing 1) that is has added international reference dosing to insulin dose adjustment 2) has contacted the SEC to seek guidance to remedy its reporting deficiencies and 3) it has authorized a private placement up to $5 million for the issuance of convertible debentures that are convertible at $0.05 per share.
A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this item 7.01.
ITEM 9.01 EXHIBITS AND FINANCIAL STATEMENTS.
Exhibit Document Description
99.1 Press Release.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated this 3rd day of October 2017.
ALR TECHNOLOGIES INC.
BY: SIDNEY CHAN
Sidney Chan
Chief Executive Officer and Chairman of the Board of Directors
